| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Total revenues | $394K-60.4% | $995K-92.2% | $12.7M+151.4% | $5.1M+50.4% | $3.4M+760.2% | $392K+1300.0% | $28K |
| Cost of sales | -$67.9M-38.0% | -$49.2M-24.2% | -$39.6M-56.2% | -$25.4M-39.4% | -$18.2M-25.9% | -$14.5M+13.6% | -$16.7M |
| Gross profit | $204.4M+35.9% | $150.4M+66.1% | $90.6M+43.3% | $63.2M+16.5% | $54.3M+57.7% | $34.4M-0.0% | $34.4M |
| Selling, general and administrative | $152.9M+18.5% | $129.1M+55.3% | $83.1M+42.7% | $58.2M+41.0% | $41.3M+32.2% | $31.2M-5.6% | $33.1M |
| Research and development | $20.9M+71.2% | $12.2M+83.9% | $6.7M+118.1% | $3.0M-72.5% | $11.1M+359.3% | $2.4M+15.8% | $2.1M |
| Impairment of long-lived assets | $253K-33.4% | $380K | — | — | — | $363K-91.0% | $4.0M |
| Total operating expenses | $173.9M+22.8% | $141.5M+57.1% | $90.1M+47.0% | $61.3M+16.4% | $52.6M+54.7% | $34.0M-13.2% | $39.2M |
| Income from operations | $30.5M+245.9% | $8.8M+1946.9% | $431K-77.5% | $1.9M+18.9% | $1.6M+319.2% | $385K+108.0% | -$4.8M |
| Interest expense, net | -$24.2M-6.1% | -$22.8M-6.9% | -$21.3M-194.4% | -$7.2M-33.3% | -$5.4M-143.1% | -$2.2M+10.6% | -$2.5M |
| Investment (loss) gain from Eton Pharmaceuticals | -$3.2M-202.6% | $3.1M | — | -$2.9M+71.2% | -$10.1M-411.1% | $3.3M-18.0% | $4.0M |
| Loss on extinguishment of debt | -$7.8M-41.8% | -$5.5M | — | — | — | — | — |
| Other income (expense), net | $47K+125.4% | -$185K+58.3% | -$444K-535.3% | $102K-48.2% | $197K+369.9% | -$73K-111.6% | $630K |
| Total other expense, net | -$31.9M-22.0% | -$26.1M-8.3% | -$24.1M-51.5% | -$15.9M+18.3% | -$19.5M-412.8% | -$3.8M-181.2% | $4.7M |
| Loss before income taxes | -$1.4M+92.1% | -$17.3M+27.0% | -$23.7M-69.2% | -$14.0M+21.6% | -$17.9M-423.4% | -$3.4M-2818.8% | -$117K |
| Income tax expense | -$3.8M-2242.2% | -$161K+77.0% | -$701K-834.7% | -$75K+43.6% | -$133K-3225.0% | -$4K-150.0% | $8K |
| Net loss | -$5.1M+70.6% | -$17.5M+28.4% | -$24.4M-73.3% | -$14.1M+21.8% | -$18.0M-436.4% | -$3.4M-2098.2% | $168K |
| Basic net loss per share of common stock | -$0.14+71.4% | -$0.49+34.7% | -$0.75-47.1% | -$0.51+26.1% | -$0.69 | — | $0.01 |
| Diluted net loss per share of common stock | -$0.14+71.4% | -$0.49+34.7% | -$0.75-47.1% | -$0.51 | — | — | $0.01 |
| Weighted average number of shares of common stock outstanding, basic | 36.8M+3.1% | 35.7M+9.3% | 32.6M+18.8% | 27.5M+2.6% | 26.8M | — | 25.32B |
| Weighted average number of shares of common stock outstanding, diluted | 36.8M+3.1% | 35.7M+9.3% | 32.6M+18.8% | 27.5M | — | — | 26.47B |
| Product Sales Net [Member] | |||||||
| Other Revenues [Member] | |||||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.